Vol.65 No.4 July 2017

A proposal for the future for the Japanese Society of Chemotherapy Part 2. World trend of the development of antimicrobial agents

Masatoshi Konno, M.D., Ph.D.

Jpn. J. Chemother. 65 (4): 531-551, 2017

Activity of the pharmacists with expertise in infection control in small- to medium-scale hospitals

Masami Tsugita

Jpn. J. Chemother. 65 (4): 552-557, 2017

Diagnosis and treatment of SFTS

Masaki Yasukawa

Jpn. J. Chemother. 65 (4): 558-563, 2017

The role of infectious disease chemotherapy pharmacist and support for inpatient pharmacists: The field of urology

Satoshi Fujii, Kaoru Yoshioka, Yusuke Kunimoto, Shogo Seiji, Yoshiki Hiyama, Satoshi Takahashi, Naoya Masumori and Atsushi Miyamoto

Jpn. J. Chemother. 65 (4): 564-567, 2017

Influences of biologics on infection and chemotherapy

Akira Watanabe

Jpn. J. Chemother. 65 (4): 568-576, 2017

In vitro and in vivo antibacterial activity of tosufloxacin against Mycoplasma pneumoniae from pediatric patients

Makoto Kaeriyama, Yoshimi Oonishi, Yuri Furuya, Nami Kudo and Yoshitaka Katakuse

Jpn. J. Chemother. 65 (4): 577-584, 2017

A phase III, randomized, open-label study on 15% tosufloxacin granules in pediatric Mycoplasma pneumoniae pneumonia

Kazunobu Ouchi, Shinichiro Takayama, Yoshitake Fujioka, Keisuke Sunakawa† and Satoshi Iwata

Jpn. J. Chemother. 65 (4): 585-596, 2017

Safety of caspofungin in patients with moderate hepatic dysfunction

Tomoko Matsuoka, Yasutaka Shinoda, Kengo Ohashi, Shinya Yoshida, Misa Kato, Takayuki Mori, Tomoaki Yoshimura and Hitomi Teramachi

Jpn. J. Chemother. 65 (4): 597-601, 2017